CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda’s oncology research and development efforts..

芝加哥--（商业新闻短讯）--Tempus AI，Inc.（纳斯达克：TEM），一家领先采用人工智能来推进精准医学和患者护理的技术公司，今天宣布扩大与武田（东京证交所：4502/纽约证交所：TAK）的合作，该公司采用数据优先的研究和开发方法，旨在加强武田的肿瘤学研究和开发工作。。

After an initial collaboration that leveraged Tempus’ de-identified multimodal datasets, this new agreement will expand upon that work. Takeda will combine Tempus’ multimodal real-world datasets and Tempus’ biological modeling capabilities to advance Takeda’s pipeline of cancer therapeutics, which includes antibody-drug conjugates (ADCs), small molecules, bispecifics and gamma delta T-cell therapies..

在利用Tempus的去识别多模式数据集进行初步合作之后，这项新协议将扩展这项工作。武田将结合Tempus的多模式现实世界数据集和Tempus的生物建模能力，推进武田的癌症治疗管道，其中包括抗体-药物偶联物（ADC），小分子，双特异性和γ-δT细胞疗法。。

Takeda researchers will use Tempus’ analytics platform, Lens, to gain real-time access to de-identified patient records as well as a suite of AI-enabled tools to accelerate critical insights for Takeda’s drug development efforts. Initial work has resulted in research that will be presented at an upcoming medical congress..

武田研究人员将使用Tempus的分析平台Lens实时访问未识别的患者记录，以及一套支持人工智能的工具，以加速对武田药物开发工作的重要见解。初步工作产生的研究成果将在即将举行的医学大会上发表。。

In parallel, the two companies have embarked on a multi-phase biological modeling project leveraging one of the largest repositories of patient-derived tumor organoids in the world. Each organoid model can be used to reflect the biology of a distinct patient tumor, and then be genetically linked through Tempus’ next-generation sequencing assays to Tempus’ real-world multimodal dataset, potentially enhancing the predictability of a drug’s effectiveness.

与此同时，这两家公司已经开始了一个多阶段的生物建模项目，利用世界上最大的患者来源的肿瘤类器官库之一。每个类器官模型都可以用来反映不同患者肿瘤的生物学特性，然后通过Tempus的下一代测序分析与Tempus的现实世界多模式数据集进行遗传关联，从而潜在地增强了药物有效性的可预测性。

This approach enables efficient hypothesis generation and rapid validation that could guide early drug candidate prioritization. For this unique scope of work, Tempus is working with Takeda on a panel of 60 organoids spanning 10 cancer indications that closely reflect real-world patients to functionally evaluate several preclinical candidates..

这种方法可以实现有效的假设生成和快速验证，从而可以指导早期候选药物的优先排序。对于这一独特的工作范围，Tempus正在与武田合作，研究一组60种类器官，涵盖10种癌症适应症，这些适应症密切反映了现实世界的患者，以功能评估几种临床前候选人。。

“We are excited to expand our relationship with Takeda, combining real-world multimodal data and biological modeling capabilities to better understand targets of interest,” said Ryan Fukushima, Chief Operating Officer at Tempus. “The results we’ve seen thus far demonstrate how the collaboration between the Takeda and Tempus teams can assist in efforts to accelerate Takeda’s growing oncology therapeutic pipeline, which may lead to the next generation of cancer treatments.”.

Tempus首席运营官瑞安·福岛（RyanFukushima）表示：“我们很高兴扩大与武田的关系，将现实世界的多模式数据和生物建模能力相结合，以更好地了解感兴趣的目标。”。“到目前为止，我们看到的结果表明，武田和Tempus团队之间的合作可以帮助加速武田不断增长的肿瘤治疗管道，这可能会导致下一代癌症治疗。”。

About Tempus

关于Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Tempus是一家通过人工智能在医疗保健中的实际应用来推进精准医学的技术公司。Tempus拥有世界上最大的多模式数据库之一，并拥有一个可访问和有用的操作系统，为医生提供支持AI的精准医学解决方案，以提供个性化的患者护理，同时促进最佳治疗方法的发现，开发和交付。

The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com..

目标是通过为医生提供工具，让每位患者在公司收集更多数据时学习，从而从之前的其他患者的治疗中受益。有关更多信息，请访问tempus.com。。

Forward Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties.

本新闻稿包含经修订的《1933年证券法》（“证券法”）第27A节和经修订的《1934年证券交易法》第21E节所指的有关Tempus和Tempus行业的前瞻性声明，涉及重大风险和不确定性。

All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of the collaboration with Takeda to use data and biological modeling to advance therapeutic research and discovery.

除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明，包括但不限于有关与武田合作使用数据和生物建模推进治疗研究和发现的预期结果和益处的声明。

In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions.

在某些情况下，您可以识别前瞻性陈述，因为它们包含诸如“预期”、“相信”、“沉思”、“继续”、“可能”、“估计”、“预期”、“将要”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“应该”、“目标”、“将要”或“将要”等词或其他类似术语或表达的否定词。

Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release..

Tempus提醒您，上述内容可能不包括本新闻稿中的所有前瞻性声明。。

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects.

。Tempus在本新闻稿中所载的前瞻性声明主要基于其对未来事件和趋势的当前预期和预测，它认为这些事件和趋势可能会影响Tempus的业务、财务状况、经营成果和前景。

These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future.

这些前瞻性报表存在与以下相关的风险和不确定性：Tempus的财务业绩；吸引和留住客户和合作伙伴的能力；管理Tempus的增长和未来支出；竞争和新市场进入者；遵守新的法律、法规和执行行动，包括人工智能领域任何不断发展的法规；维护、保护和增强Tempus知识产权的能力；吸引和留住合格团队成员和关键人员的能力；偿还或再融资未偿债务或获得额外融资的能力；未来收购、资产剥离或投资；气候变化、自然灾害、健康流行病、宏观经济状况、战争或其他武装冲突的潜在不利影响，以及Tempus向美国证券交易委员会（“SEC”）提交的截至2024年6月30日季度的10-Q表季度报告中题为“风险因素”的部分中描述的风险、不确定性和其他因素，以及Tempus未来可能向SEC提交的其他文件中描述的因素。

In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new in.

此外，本新闻稿中包含的任何前瞻性声明均基于Tempus认为截至目前合理的假设。Tempus没有义务更新任何前瞻性声明，以反映本新闻稿发布日期后的事件或情况，或反映新的情况。